Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Samsung Electronics | Eli Lilly and Company | Montage Technology | |
|---|---|---|---|
| Moat rating | narrow Samsung leads three of its four principal markets — Q1 2026 DRAM revenue share 38.5% ($37.32B, TrendForce, https://www.trendforce.com/presscenter/news/20260601-13070.html), Q1 2026 NAND share 31.6% ($13.51B, TrendForce, https://www.trendforce.com/presscenter/news/20260525-13058.html), and #1 in Q2 2026 smartphones at 24% (Counterpoint via Android Authority, https://www.androidauthority.com/counterpoint-research-q2-2026-smartphone-shipment-report-3686931/) — but the moat is narrow, not wide: memory economics are violently cyclical (industry DRAM revenue swung +81% QoQ on contract-price spikes per the same TrendForce release), SK hynix holds the highest HBM bit-shipment mix among the top three (same release), and foundry trails TSMC 6.5% vs ~72% share (TrendForce data via TelecomLead, https://telecomlead.com/semiconductor/global-foundry-market-hits-record-47-95-bn-in-q1-2026-as-ai-chip-demand-drives-growth-tsmc-expands-share-to-72-126247). | wide Eli Lilly's FY2025 10-K states "Intellectual property protection is critical" and that compound patents provide roughly 20-year market exclusivity ("patents in each relevant country last for a period of 20 years"), warning that loss of patent protection causes a "severe and rapid decline in revenues." Backed by an 83.0% gross margin (up from 81.3% in 2024) and a fast-growing, patent-protected incretin franchise (Mounjaro +99%, Zepbound +175% in 2025), the economic moat is wide and durable. Source: LLY FY2025 10-K. | narrow The 2026 interim results announcement (published 2026-08-28) cites Frost & Sullivan that in 2024 'the global memory interconnect chip market was highly concentrated, with the top three players accounting for 93.4% of total revenue; we ranked first globally with a market share of approximately 36.8%', and reports H1 2026 gross margin of 65.3%, up 4.87 percentage points. That is a real and profitable position, but its durability is not established: the 2025 annual report (https://www.hkexnews.hk/listedco/listconews/sehk/2026/0424/2026042404088.pdf) warns that 'Early-mover advantages are critical to our ability to capture market share. If competitors launch next-generation products ahead of us during product cycles, we may lose substantial market share', says the DDR5 iteration cycle 'has shortened to 12 to 18 months', and says Samsung Electronics, SK Hynix and Micron Technology 'collectively account for more than 90% of the global server DRAM market'. The lead has to be re-won every sub-generation, in a market whose top three suppliers held 93.4% of 2024 revenue and whose server-DRAM end market three companies hold more than 90% of. And on July 15, 2026 Seoul prosecutors searched the Group's South Korean office in an investigation of a potential competition-law violation (no charges as of the announcement). Narrow, not wide. |
| Moat type | cost scale The durable advantage is manufacturing scale and capital intensity: the top three DRAM suppliers take roughly $8.97 of every $10 of industry revenue (Samsung 38.5% + SK hynix 28.8% + Micron 22.4% in Q1 2026 per TrendForce, https://www.trendforce.com/presscenter/news/20260601-13070.html), a structure sustained by multi-billion-dollar fab economics that has admitted no new large entrant in decades; Samsung is the largest-revenue producer in both DRAM and NAND (TrendForce, https://www.trendforce.com/presscenter/news/20260525-13058.html). | intangibles ip Per the LLY FY2025 10-K, the pharma protection "anticipated to be of most relevance" is "patents claiming the active ingredient (the compound patent)," supplemented by regulatory data protection, FDA approvals, and brands — i.e., intangible assets. The 10-K notes that without such protection, products face intense generic and biosimilar price competition that erodes revenue quickly. | efficient scale The filing locates the protection in the cost and time of entry, not in exclusive IP: 'Memory interconnect chips feature high entry barriers in terms of R&D capabilities and technical expertise. New entrants require years of intensive R&D to keep pace with the latest industry standards and product iteration cycles, while also completing stringent product validation and qualification processes', and the chips must 'undergo rigorous qualification processes from server CPU vendors and memory modules manufacturers before they can be deployed at scale in commercial applications'. The products are built to open standards ('Leveraging open industry standards, we have established ourselves as a market leader in memory interconnect'), so rivals can and do build compliant parts; what keeps the field small is a market the report's Frost & Sullivan data estimate at USD1,579 million for 2025, in which the top three held 93.4% of 2024 revenue. Montage's role as JEDEC spec owner of DDR5 RCD, MDB and CKD chips is its head start inside that oligopoly, not a lock that excludes the other two. |
| Leadership | co leader Revenue leader in DRAM (38.5%) and NAND (31.6%) in Q1 2026 (TrendForce) and #1 in Q2 2026 smartphone shipments (Counterpoint), but not the leader where AI value concentrates: SK hynix has the highest HBM bit-shipment mix among the top three DRAM suppliers (TrendForce, https://www.trendforce.com/presscenter/news/20260601-13070.html) and TSMC dominates foundry with ~72% share to Samsung's 6.5% (TrendForce via TelecomLead). | co leader Duopoly with Novo Nordisk: Novo's own FY2025 20-F names "Novo Nordisk and Eli Lilly [as] the most significant companies measured by market share" in the global diabetes and GLP-1 markets. Lilly is ascendant — the 20-F concedes Wegovy's years-long US anti-obesity prescription lead "was overtaken by a competing GLP-1 based product in the beginning of 2025" (Lilly's tirzepatide) — but Novo still cites Ozempic as "the leading product by sales," so co-leader is the honest band. Sources: Novo Nordisk FY2025 20-F; LLY FY2025 10-K. | co leader Frost & Sullivan, as cited in the interim announcement, ranks Montage first in 2024 memory interconnect chips at approximately 36.8%, with the top three at 93.4%. The two unnamed rivals therefore out-earn Montage combined, and its margin over second place is not disclosed. The company says it 'maintained our global leadership in the DDR5 generation' and calls itself 'one of the only two suppliers of DDR5 Gen 1 MRCD/MDB chips in the world'. In 2024 PCIe Retimers it is second at around 10.9%, in a market where 'the top two companies captured 96.9%'. It is first by revenue in its core market, but inside a three-way oligopoly rather than clear of it. |
| Pricing power | moderate Current pricing is extraordinary but cyclical, not structural: conventional DRAM contract prices rose roughly 93-98% QoQ in Q1 2026 (TrendForce, https://www.trendforce.com/presscenter/news/20260601-13070.html) — shortage-driven commodity pricing that reverses in downcycles. The set-side shows the limit: Samsung's own MX (smartphone) division posted a KRW 0.7 trillion operating loss in Q2 2026 on elevated component costs (Samsung Newsroom, https://news.samsung.com/global/samsung-electronics-announces-second-quarter-2026-results). | moderate Mixed. The LLY 10-K shows an 83.0% gross margin (up 1.7pp), evidence of strong list-price power on exclusive branded drugs; but it repeatedly notes 2025 revenue growth was "partially offset by lower realized prices" for both Mounjaro and Zepbound, alongside heavy PBM/formulary rebate pressure and default anti-obesity coverage restrictions (e.g., US self-insured employers "must generally opt in" for obesity-drug coverage). Net pricing power is therefore moderate, not strong. | moderate Margins are high and rising. The 2025 annual report (https://www.hkexnews.hk/listedco/listconews/sehk/2026/0424/2026042404088.pdf) gives gross margin of 62.2% in 2025 against 58.1% in 2024, and the interim gives 65.3% for H1 2026, with interconnect chips at 69.3%. But the interim attributes the increase 'mainly' to 'the increase in the proportion of sales revenue of products with higher gross profit margin', which is mix, not price. The buyer side is concentrated. The annual report says the five largest customers took 77.2% of revenue and the largest 29.7%, and it warns that 'significant customer pricing demands or intensified competition, may lead to volatility in our market share and a decline in revenue'. Separately, on July 15, 2026 the Fair Trade Investigation Division of the Seoul Central District Prosecutors' Office began a search and seizure at the Group's South Korean office over 'a potential competition law violation'. Per the Group's July 16, 2026 announcement (https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0717/2026071700057.pdf), none of the Group, its directors or employees had been charged. The Standard (https://www.thestandard.com.hk/finance/article/337444/Montage-Technology-shares-drop-229pc-amid-fair-trade-violation-suspicions, 2026-07-16) reports that prosecutors raided Montage, Renesas Electronics and Rambus 'on suspicion of violating fair trade acts and manipulating prices'. |
| Summary | Samsung Electronics is the world's largest memory maker and a vertically integrated device company. In Q1 2026 it was #1 in DRAM (38.5% revenue share) and #1 in NAND (31.6%), and in Q2 2026 it retook #1 in global smartphones at 24% share. The AI-datacenter memory shortage produced record results: Q2 2026 company revenue of KRW 171.5 trillion and an all-time-high operating profit of KRW 89.5 trillion, with server memory reaching a record share of the sales mix and HBM4E samples shipped to major customers (Samsung Newsroom). The caveats that keep the moat narrow: the profit pool is a price cycle, not a structural annuity; SK hynix leads the highest-value HBM segment by bit-shipment mix; and Samsung Foundry, at 6.5% share versus TSMC's ~72%, remains a distant second in leading-edge logic despite expanding 2nm design wins. | Lilly's moat rests on patent-protected, FDA-approved branded medicines led by its tirzepatide incretin franchise: per the FY2025 10-K, Mounjaro ($22.97B) and Zepbound ($13.54B) together generated roughly 56% of 2025's $65.2B revenue (up 99% and 175% respectively), while compound patents confer ~20-year market exclusivity and support an 83.0% gross margin. Durable competition only emerges after patents and regulatory data protection lapse, at which point the 10-K warns generics and biosimilars drive a "severe and rapid decline in revenues." | Montage is a fabless designer of interconnect chips for servers and PCs: DDR5 memory interface chips (RCD/DB), MRCD/MDB for high-bandwidth MRDIMM modules, CKD clock drivers for PC modules, module supporting chips (SPD, PMIC and TS), PCIe Retimers and CXL MXC memory-expander controllers, plus a smaller Jintide x86 server-CPU line built 'With the x86 cores that we procured from Intel'. Its edge is standards leadership in a concentrated niche. It invented the DDR4 '1+9' buffered architecture that was 'ultimately adopted as a JEDEC international standard', it is JEDEC spec owner of DDR5 RCD, MDB and CKD chips, and Frost & Sullivan, as cited in the interim, ranks it first in 2024 memory interconnect chips at approximately 36.8%, with the top three at 93.4%. It extended into PCIe Retimers on in-house SerDes IP and, on the same Frost & Sullivan data, ranked second in 2024 at around 10.9%, as a self-described new entrant. H1 2026 revenue was RMB3,335 million, up 26.7%, with interconnect-chip gross margin of 69.3%. The weaknesses are structural. Per the 2025 annual report, its direct customers for memory chips are module makers in a server DRAM market that three companies hold more than 90% of, and the five largest customers took 77.2% of 2025 revenue. South Korea accounted for RMB2,925 million of RMB5,456 million in 2025 revenue. And on July 15, 2026 the Seoul Central District Prosecutors' Office searched the Group's Korean office in an investigation of a potential competition-law violation. |
| Chain position | Upstream supplier of DRAM/HBM and NAND to the AI datacenter buildout (server memory at a record share of its Q2 2026 sales mix; HBM4E samples shipped to major customers) and a contract foundry, while simultaneously a downstream device maker (Galaxy) that consumes its own components (Samsung Newsroom, https://news.samsung.com/global/samsung-electronics-announces-second-quarter-2026-results). | Upstream branded-drug originator. Per the FY2025 10-K, US distribution flows through three wholesalers (McKesson, Cencora, Cardinal Health), each accounting for over 10% of consolidated revenue, into consolidated PBMs/payers whose formularies and rebate demands constrain net price; Lilly is also expanding a direct-to-patient channel, LillyDirect. | Upstream fabless chip supplier. Per the 2025 annual report, memory interface and supporting chips go to memory module manufacturers ('our direct customers being memory module manufacturers'), and PCIe Retimers go to server OEMs/ODMs as direct customers, with cloud providers as end users. Wafer fabrication, packaging and testing are outsourced, and the five largest suppliers were 79.4% of 2025 purchases. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.13 at weight 0.20 · swarm bullish Editorial prior, not backtested. | +0.30 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.13 at weight 0.20 · swarm neutral Editorial prior, not backtested. |